A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
Key Details
- 1The Path-IO model uses AI to analyze digital pathology slides from NSCLC patients.
- 2Tested on 797 patients (MD Anderson) and validated on 280 international patients (including Lung-MAP S1400I trial).
- 3The model stratified patients into high- and low-risk groups, doubling risk in the high-risk cohort.
- 4Path-IO outperformed PD-L1 biomarker: Path-IO C-indices up to 0.69 (OS) and 0.65 (PFS); PD-L1 indices as low as 0.50-0.58.
- 5Integrating radiomics and clinical data improved prediction performance further (C-index for OS to 0.75, PFS to 0.70).
- 6Study validated across real-world and phase III trial cohorts, though retrospective; prospective validation is the next step.
Why It Matters
This work demonstrates that advanced AI analysis of digital pathology can outperform traditional biomarkers in predicting immunotherapy outcomes. If validated further, such tools could help personalize treatment for cancer patients, offering a significant advance in precision oncology and imaging AI.
Source
EurekAlert
Related News
•EurekAlert
AI Analyzes 66,000 MRI Scans to Map Body Composition Risks
Researchers used AI to analyze over 66,000 whole-body MRI scans, creating a detailed body composition reference map linked to health risks.
•EurekAlert
Brain-Inspired Training Enhances AI Reliability and Uncertainty Recognition
KAIST researchers developed a brain-inspired AI training method that reduces overconfidence and improves the recognition of unfamiliar data.
•EurekAlert
AI and PS-OCT Enhance Early Keratoconus Detection
AI combined with polarization-sensitive OCT enables earlier and more accurate detection of subclinical keratoconus compared to standard tomography.